| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
|
BALATON [A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion] COMINO [A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion] |
Total: BALATON - BRVO: N = 553 COMINO - CRVO: N = 729 |
Genentech/Hoffman-La Roche BALATON: NCT04740905 COMINO: NCT04740931 |
BALATON Primary completion: July 2022 Study completion: June 2023 COMINO Primary completion: August 2022 Study completion: July 2023 |
Tadayoni R, Paris LP, Danzig CJ, et al. Efficacy and safety of faricimab for macular edema due to retinal vein occlusion: 24-week results from the BALATON and COMINO trials. Ophthalmology. Published online January 25, 2024. doi.org/10.1016/j.ophtha.2024.01.029 |
 (Pg 4)[Khanani.Macula Society.2023] |